SCHEMBL6790812

SCHEMBL6790812

O=C(NCCCCCc1nc2ccccc2c(=O)[nH]1)OCc1ccccc1

nearest known ligand 0.59

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
TNKS O95271 2/20 0.59
TNKS2 Q9H2K2 1/20 0.59
SMN1; SMN2 Q16637 1/20 0.57
KDM4E B2RXH2 2/20 0.56
LMNA P02545 1/20 0.56
CYP2C9 P11712 1/20 0.53
CYP2C19 P33261 1/20 0.53
PARP1 P09874 7/20 0.52
PARP2 Q9UGN5 2/20 0.52
TGM2 P21980 1/20 0.51
PARP3 Q9Y6F1 3/20 0.50
HTT P42858 1/20 0.50
MAPT P10636 1/20 0.49
KMT2A Q03164 1/20 0.49
ALDH1A1 P00352 1/20 0.48
PDE10A Q9Y233 1/20 0.47
TP53 P04637 1/20 0.47
G6PD P11413 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6798298 0.78 PARP1 (0.60) TNKS2PARP1PARP2MAPTKMT2A
SCHEMBL8324238 0.78 GAA (0.67) SMN1; SMN2LMNAHTTMAPT
SCHEMBL30176852 0.77 PARP1 (0.73) TNKS2LMNAPARP1PARP2KMT2A
SCHEMBL9874334 0.77 HTT (0.79) SMN1; SMN2LMNATGM2HTTMAPT
SCHEMBL9340146 0.77 HTT (0.79) SMN1; SMN2LMNATGM2HTTMAPT
SCHEMBL15346534 0.77 HTT (0.79) SMN1; SMN2LMNATGM2HTTMAPT
SCHEMBL6795780 0.77 PARP1 (0.61) TNKS2SMN1; SMN2PARP1PARP2KMT2A
SCHEMBL30495495 0.76 PARP1 (0.64) TNKSSMN1; SMN2CYP2C9CYP2C19PARP1
SCHEMBL29040111 0.76 PARP1 (0.64) TNKSSMN1; SMN2CYP2C9CYP2C19PARP1
SCHEMBL2884188 0.76 KDM4E (0.56) SMN1; SMN2KDM4ELMNACYP2C9CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040077667-A1 Quinazolinone derivatives FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2004-04-22 US disclosed
EP-1355888-A1 QUINAZOLINONE DERIVATIVES FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2003-10-29 EP disclosed
WO-2002048117-A1 QUINAZOLINONE DERIVATIVES FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2002-06-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040077667-A1 Quinazolinone derivatives PARP1, PARP9, PARP2 TNKS 11/4885TNKS2 32/4885SMN1; SMN2 3583/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.